Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group box 3 pseudogene 1 (HMGB3P1) is a pseudogene related to the high mobility group box protein family, located in humans and also referenced as HMG4L, HMGB3L1, or dJ18C9.3[1][3][5][6]. As a pseudogene, HMGB3P1 is considered a non-functional genetic remnant; it shares sequence similarity with functional genes but does not encode a functional protein due to the accumulation of disabling mutations or regulatory silencing[2]. There is no evidence that HMGB3P1 serves as a therapeutic target (such as a receptor, enzyme, transporter, or transcription factor), nor is it known to directly participate in canonical biological processes, disease mechanisms, or drug–target interactions. While some pseudogenes can have regulatory roles at the RNA level, there are no established data or therapeutic implications for HMGB3P1 in these contexts[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group box 3 pseudogene 1 (HMGB3P1).